WO2000042026A1 - Non-peptide glp-1 agonists - Google Patents
Non-peptide glp-1 agonists Download PDFInfo
- Publication number
- WO2000042026A1 WO2000042026A1 PCT/DK2000/000014 DK0000014W WO0042026A1 WO 2000042026 A1 WO2000042026 A1 WO 2000042026A1 DK 0000014 W DK0000014 W DK 0000014W WO 0042026 A1 WO0042026 A1 WO 0042026A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- cycloalkyl
- aryl
- heterocyclyl
- compound according
- Prior art date
Links
- 0 *c(c(*)c(*)c1n2)c(*)c1nc(*)c2Cl Chemical compound *c(c(*)c(*)c1n2)c(*)c1nc(*)c2Cl 0.000 description 3
- DZBRZBGMDWBDHD-UHFFFAOYSA-O CC(C)CC[S+](c1nc(ccc(Cl)c2)c2nc1C(F)(F)F)(O)=O Chemical compound CC(C)CC[S+](c1nc(ccc(Cl)c2)c2nc1C(F)(F)F)(O)=O DZBRZBGMDWBDHD-UHFFFAOYSA-O 0.000 description 1
- RWPHLQMALCAXRT-UHFFFAOYSA-N CC(C)c1nc(cc(c(Cl)c2)Cl)c2nc1S(C)(=O)=O Chemical compound CC(C)c1nc(cc(c(Cl)c2)Cl)c2nc1S(C)(=O)=O RWPHLQMALCAXRT-UHFFFAOYSA-N 0.000 description 1
- GOFBFCFUFDFZRA-UHFFFAOYSA-N CC(C)c1nc(cc(c(Cl)c2)Cl)c2nc1S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)c1nc(cc(c(Cl)c2)Cl)c2nc1S(c1nc(C)c[s]1)(=O)=O GOFBFCFUFDFZRA-UHFFFAOYSA-N 0.000 description 1
- HTWIZMNMTWYQRN-UHFFFAOYSA-N CC1OCCO1 Chemical compound CC1OCCO1 HTWIZMNMTWYQRN-UHFFFAOYSA-N 0.000 description 1
- QRAAFZJXXUFLKI-UHFFFAOYSA-N CCCc1nc(cc(c(Cl)c2)Cl)c2nc1S(c1nc(C)c[s]1)=O Chemical compound CCCc1nc(cc(c(Cl)c2)Cl)c2nc1S(c1nc(C)c[s]1)=O QRAAFZJXXUFLKI-UHFFFAOYSA-N 0.000 description 1
- KAOBTFUQYVEKNF-OVCLIPMQSA-N CCOc(ccc1n2)cc1cc(/C=N/OC)c2Cl Chemical compound CCOc(ccc1n2)cc1cc(/C=N/OC)c2Cl KAOBTFUQYVEKNF-OVCLIPMQSA-N 0.000 description 1
- OXBAIBSPQGRDAU-UHFFFAOYSA-N CS(Cc1nc(cc(c(Cl)c2)Cl)c2nc1S(C)(=O)=O)(=O)=O Chemical compound CS(Cc1nc(cc(c(Cl)c2)Cl)c2nc1S(C)(=O)=O)(=O)=O OXBAIBSPQGRDAU-UHFFFAOYSA-N 0.000 description 1
- AYQQKYCVOJWCIA-UHFFFAOYSA-N CS(c1nc(cc(c(Cl)c2)Cl)c2nc1NC1CC1)(=O)=O Chemical compound CS(c1nc(cc(c(Cl)c2)Cl)c2nc1NC1CC1)(=O)=O AYQQKYCVOJWCIA-UHFFFAOYSA-N 0.000 description 1
- UKCNLDFGBFRBRT-UHFFFAOYSA-N C[N]1(CCOCCC1)O Chemical compound C[N]1(CCOCCC1)O UKCNLDFGBFRBRT-UHFFFAOYSA-N 0.000 description 1
- JSMMZMYGEVUURX-UHFFFAOYSA-N Cc([s]1)ccc1Cl Chemical compound Cc([s]1)ccc1Cl JSMMZMYGEVUURX-UHFFFAOYSA-N 0.000 description 1
- MGHKWBQZEBMFOH-UHFFFAOYSA-N Cc1c(C)[o]nc1C Chemical compound Cc1c(C)[o]nc1C MGHKWBQZEBMFOH-UHFFFAOYSA-N 0.000 description 1
- OBSLLHNATPQFMJ-UHFFFAOYSA-N Cc1c[s]c(C)n1 Chemical compound Cc1c[s]c(C)n1 OBSLLHNATPQFMJ-UHFFFAOYSA-N 0.000 description 1
- NOCVFNIGNZYYRD-UHFFFAOYSA-N Cc1cc(F)cc2c1COCO2 Chemical compound Cc1cc(F)cc2c1COCO2 NOCVFNIGNZYYRD-UHFFFAOYSA-N 0.000 description 1
- UXRGZWKBQKBNTQ-UHFFFAOYSA-N Cc1cc(F)cc2c1OCCO2 Chemical compound Cc1cc(F)cc2c1OCCO2 UXRGZWKBQKBNTQ-UHFFFAOYSA-N 0.000 description 1
- GIWQSPITLQVMSG-UHFFFAOYSA-N Cc1ncc[n]1C Chemical compound Cc1ncc[n]1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 description 1
- QBDXSEYWEKKYSH-UHFFFAOYSA-N Cc1nnc[n]1C Chemical compound Cc1nnc[n]1C QBDXSEYWEKKYSH-UHFFFAOYSA-N 0.000 description 1
- QYSASSWEUXOZEQ-UHFFFAOYSA-N Cc1nnn[n]1-c1ccccc1 Chemical compound Cc1nnn[n]1-c1ccccc1 QYSASSWEUXOZEQ-UHFFFAOYSA-N 0.000 description 1
- DYAOXQGSIQUMBG-UHFFFAOYSA-N Cc1sc(C)n[nH]1 Chemical compound Cc1sc(C)n[nH]1 DYAOXQGSIQUMBG-UHFFFAOYSA-N 0.000 description 1
- VOZYQWJHYLSTFQ-UHFFFAOYSA-N FC(c1nc(cc(c(Cl)c2)Cl)c2nc1Sc1nc2ccccc2[o]1)(F)F Chemical compound FC(c1nc(cc(c(Cl)c2)Cl)c2nc1Sc1nc2ccccc2[o]1)(F)F VOZYQWJHYLSTFQ-UHFFFAOYSA-N 0.000 description 1
- WTCRJLULICFQDK-UHFFFAOYSA-N O=Cc(cc(cc(c(Cl)c1)Cl)c1n1)c1Cl Chemical compound O=Cc(cc(cc(c(Cl)c1)Cl)c1n1)c1Cl WTCRJLULICFQDK-UHFFFAOYSA-N 0.000 description 1
- KRCMHMGFRBKPPH-UHFFFAOYSA-N [O-][NH+](c(c([NH+]([O-])[O-])c1)cc(nc2C(F)(F)F)c1nc2-c1c(C(F)(F)F)cc(C(F)(F)F)cc1)[O-] Chemical compound [O-][NH+](c(c([NH+]([O-])[O-])c1)cc(nc2C(F)(F)F)c1nc2-c1c(C(F)(F)F)cc(C(F)(F)F)cc1)[O-] KRCMHMGFRBKPPH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Definitions
- the present invention relates to novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity.
- IGT abnormal glucose tolerance
- GLP-1 (glucagon like peptide-1 ) is a 30 amino acid long peptide hormone secreted by the L- cells in the intestine.
- GLP-1 consists of two native forms, GLP-1 (7-36) and GLP-1 (7-37), of the following amino acid sequences:
- X is NH 2 for GLP-1 (7-36) and Gly for GLP-1 (7-37).
- GLP-1 is a so-called incretin and its primary mechanisms of actions are to:
- GLP-1 a very efficient blood glucose lowering agent (1 ).
- the very efficient blood glucose lowering as well as the glucose dependency of its action makes it an ideal candidate for the treatment of Type 2 diabetes (2-10).
- GLP-1 offers something that no other existing drug or drug candidate can provide: very efficient blood glucose lowering, even in SU (sulphonylurea)-failures (6), without the risk of serious hypoglycaemia.
- GLP-1 has also been shown to increase the rate of insulin biosynthesis (12,13) and restore the ability of the ⁇ -cells to respond rapidly to rising plasma glucose in terms of first phase insulin release in rats (14).
- GLP-1 would be expected to be able to prevent or delay the progression from IGT to full blown Type 2 diabetes.
- Patients treated with GLP-1 compared to eg metformin or sulphonylureas, will be better managed and may as a result thereof have a much later transfer to insulin requiring therapy.
- GLP-1 compounds have been shown to stimulate growth and proliferation of ⁇ -cells (15-17), thereby also supporting use of GLP-1 compounds and GLP-1 agonists for increasing the number of ⁇ -cells in a patient in vivo.
- Type 2 diabetes patients may be an impaired incretin function (18,19).
- GIP Global Inhibitory Polypeptide (19,20).
- GIP Gastric Inhibitory Polypeptide
- GLP-1 The ability of GLP-1 to decrease appetite and energy intake is now firmly established, both in normal, lean people and in obese people (22-24). Obese subjects have been shown to have an attenuated GLP-1 release in response to meals (25,26). This may further add to the po- 5686.204-WO tential of GLP-1 as being able to decrease weight in Type 2 diabetes patients. This use of GLP-1 is described further in WO No 98/20895 to Novo Nordisk A/S and WO No 98/28414 to Eli Lilly and Company.
- GLP-1 is rapidly metabolised by the proteolytic enzyme Dipeptidyl Peptidase-IV (27) into an inactive or perhaps even antagonistic metabolite (28), complicating the use of GLP-1 as a drug.
- GLP-1 and analogues of GLP-1 as well as fragments thereof in the treatment of Type 1 and Type 2 diabetes and obesity are disclosed in several publications.
- GLP-1 fragments including GLP-1 (7-37) and GLP-1 (7-36), and functional derivatives thereof for use as insulinotropic agents.
- WO No 91/11457 to Buckley et al. discloses analogues of the active GLP-1 peptides 7-34, 7-35, 7-36, and 7-37 for use in the treatment of Type 2 diabetes
- WO No 98/08871 to Novo Nordisk A/S discloses derivatives of GLP-1 for use in the treatment of diabetes and obesity which are especially useful as they are both metabolically stable and very potent.
- peptides are generally not known to be orally available.
- the GLP-1 receptor is a so-called 7 transmembrane (7TM) G-protein coupled receptor. These receptors are transmembrane proteins consisting of a N-terminal extracellular part, a transmembrane core and three extracellular and three intracellular loops. The receptors are coupled to a G-protein (consisting of three subunits) and then further to an effector system.
- the effector system for the GLP-1 receptor is the adenylyl cyclase enzyme. Upon activation of the receptor, adenylyl cyclase catalyses the formation of the second messenger cAMP from ATP.
- glucagon-secretin (B) family consists of the receptors for GLP-1 , glucagon, GIP, secretin, VIP, PACAP, calcitonin, PTH, CRF, GRF and a few more.
- the (B) family is characterised by a relative large N-terminal domain of the receptor.
- the natural ligands for these receptors are all large peptides and the binding (and consecutive activation) of the receptors by their natural ligands is believed to involve both the N-terminal domain and the transmembrane region.
- They may be characterised by activating the human GLP-1 receptor without competing with GLP-1 for the GLP-1 binding site in a competition binding assay.
- G-protein coupled receptors are theoretically thought to exist in different conformations: R and R * , where R is the inactive receptor conformation and R * the active.
- R is the inactive receptor conformation
- R * the active.
- the most recent literature speculates that there may be one or more intermediate states (31 ).
- the compounds according to the invention may introduce a new model in order to accommodate their characteristics.
- this model we introduce a further receptor conformation R** which is another active receptor conformation.
- R* would then be the conformation that GLP-1 under normal circumstances stabilises where R** is the conformation that the compounds according to the invention stabilises.
- a model with two different active receptor conformations may also offer an explanation for why some of the compounds according to the invention when tested in the assays are partial and not full agonists because one conformation may be able to elicit partial agonism only and the other full agonism.
- Halogen designates an atom selected from the group consisting of F, Cl, Br or I.
- lower alkyl in the present context designates a saturated, branched or straight hydrocarbon group having from 1 to 6 carbon atoms.
- Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, fe/t-pentyl, n-hexyl, isohexyl and the like.
- lower alkenyl as used herein represents a branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, isopropenyl,
- lower alkynyl represents a branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one triple bond.
- examples of such groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 5-hexynyl, 2,4-hexadiynyl and the like.
- lower alkanoyl in the present context designates a group -C(O)-H or -C(O)-lower alkyl wherein lower alkyl has the above meaning.
- Representative examples include, but are not limited to, formyl, acetyl, propionyl, butyryl, valeryl, hexanoyl, heptanoyl and the like.
- cycloalkyl represents a saturated carbocyclic group having from 3 to 10 carbon atoms. Representative examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
- cycloalkenyl represents a carbocyclic group having from 3 to 10 carbon atoms containing at least one double bond.
- Representative examples are 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1 -cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 2-cycloheptenyl, 3-cycloheptenyl, 2-cyclooctenyl, 1 ,4-cyclooctadienyl and the like.
- heterocyclyl as used herein represents a saturated or partially unsaturated 3 to 10 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur.
- Representative examples are pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, tetrahydrofuranyl and the like.
- aryl represents a carbocyclic aromatic ring system such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl, biphenylenyl and the like.
- Aryl is also intended to include the partially hydrogenated deriva- tives of the carbocyclic aromatic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1 ,2,3,4-tetrahydronaphthyl, 1 ,4-dihydronaphthyl and the like.
- heteroaryl represents a heterocyclic aromatic ring system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur such as furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1 ,2,3-triazinyl, 1 ,2,4-triazinyl, 1 ,3,5- triazinyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,2,3-thiadiazolyl, 1 ,
- Heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated above.
- Non-limiting examples of such partially hydrogenated derivatives are 2,3-dihydrobenzofuranyl, pyrrolinyl, pyrazolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl and the like.
- Aryl-lower alkyl means a lower alkyl or alkenyl as defined above, substituted by an aryl or heteroaryl as defined above, for example:
- a non-peptide is understood to refer to any chemical compound which is not a peptide.
- a peptide is defined as a linear sequence of natural amino acids coupled by peptide bonds of a length of at least 6 amino acids including derivatives thereof wherein one or more of the amino acid residues have been chemically modified, eg by alkylation, acylation, ester formation or amide formation.
- a GLP-1 agonist is understood to refer to any compound which fully or partially activates the human GLP-1 receptor.
- a partial GLP-1 agonist is understood to refer to any compound which increases the activity of the human GLP-1 receptor but which compared to GLP-1 is not able to effect a full response (E max ⁇ 100% relative to GLP-1 ).
- a GLP-1 antagonist is understood to refer to any compound which decreases the activity of the human GLP-1 receptor seen after stimulation with GLP-1.
- an inverse GLP-1 agonist is understood to refer to any compound which not only decreases the activity of the human GLP-1 receptor seen after stimulation with GLP-1 but also decreases the activity of the non-stimulated receptor (basal activity).
- a metabolic disorder is understood to refer to any disorder associated with the metabolism or resulting from a defect of the metabolism.
- GLP-1 is understood to refer to either or both of the above two native forms GLP-1 (7-36) and GLP-1 (7-37) unless otherwise specified.
- the present invention relates to compounds of the general formula (I):
- R ⁇ R 2 , R 3 and R 4 independently are hydrogen, halogen, -CN, -CF 3 , -NO 2 , -OR 5 , lower alkyl, -SR 5 , -S(O) 2 NR 5 R 6 , -S(O)NR 5 R 6 , -S(O) 2 R 5 , -S(O)R 5 , -C(O)NR 5 R 6 , -CH 2 OR 5 , -CH 2 NR 5 R 6 , -NR 5 R 6 , -C(O)R 5 or -C(O)OR 5 , wherein R 5 and R 6 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkyny
- D is hydrogen, halogen, -CN, -CF 3 , -NO 2 , -OR 7 , -NR 7 R 8 , lower alkyl, aryl, -C(O)NR 7 R 8 , -CH 2 OR 7 , -CH 2 NR 7 R 8 or -C(O)OR 7 ,
- R 7 and R 8 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alky
- R 9 , R 9a and R 9b independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl- lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl
- R 9c and R 9d independently are hydrogen or lower alkyl
- n, r independently are 0, 1 , 2, 3 or 4,
- a and B independently are hydrogen, halogen, -CF 3 , -CF 2 CF 3 , -CN, -NO 2 , lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, hydroxy, in which the cycloalkyl ring may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, -CH 2 OH, -NO 2 , -CN, -C(O)OH, -O-lower alkyl, -C(O)OCH 3 , -C(O)NH 2 , -OCH 2 C(O)NH 2 , -NH 2 , -N(CH 3 ) 2 , -CH 2 N(CH 3 ) 2 , -SO 2 NH 2 , -OCHF 2 , -CF 3 and -OCF 3 , or A and B independently are hydrogen, halogen, -CF 3
- p 1 , 2 or 3
- G is -CR 18a R 18 ⁇ -NO " -, -NR 19 -, -O- or -S-,
- K is -CR 18c R 8d -, -NR 20 , -O- or -S-,
- R 0 , R 11 , R 2 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 18a , R 18b , R 8c and R 18 ⁇ independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -OCF 2 CHF 2 , -NO 2 , -OR 21 , -NR 21 R 22 , lower alkyl, lower 5686.204-WO alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkynyl, cycloalkenyl-lower al
- R 21 and R 22 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloal- kenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower
- R 19 and R 20 independently are hydrogen, -OR 23 , -NR 23 R 24 , lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower al- 5686.204-WO kenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl
- R 23 and R 24 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, het- eroaryl-lower alkenyl or heteroaryl-lower alkynyl, or R 23
- q 1 , 2 or 3
- s 0, 1 , 2 or 3,
- a and B may be connected and together form a C 2 . 3 -alkylene radical
- L represents a group wherein n or r is 0, A is not halogen, -CN or -NO 2 , and
- M represents a group wherein n or r is 0, B is not halogen, -CN or -NO 2 ,
- the compounds have the general formula (II):
- R ⁇ R 2 , R 3 , R 4 , L, M, A and B are as defined for formula (I).
- R 1 , R 2 , R 3 , R 4 , L, M, A and B are as defined for formula (I).
- R ⁇ R 2 , R 3 and R 4 are preferably independently hydrogen, halogen, -CN, -CF 3 , -NO 2 , lower alkyl, lower alkoxy, -S(O) 2 NR 5 R 6 , -S(O)NR 5 R 6 , -S(O) 2 R 5 , -C(O)NR 5 R 6 , -SR 5 , -C(O)R 5 or -C(O)OR 5 , wherein R 5 and R 6 are as defined for formula (I).
- R 1 , R 2 , R 3 and R 4 are independently hydrogen, halogen, -CN, -CF 3 , lower alkyl, lower alkoxy, -SR 5 , -S(O) 2 R 5 , -C(O)OR 5 , -C(O)R 5 , -NO 2 or -C(O)NR 5 R 6 , wherein R 5 and R 6 are as defined for formula (I).
- R 5 and R 6 are preferably independently hydrogen, phenyl or lower alkyl, wherein phenyl optionally is substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, -CH 2 OH, -NO 2 , -CN, -C(O)OH, 5686.204-WO -O-lower alkyl, -C(O)OCH 3 , -C(O)NH 2 , -OCH 2 C(O)NH 2 , -NH 2 , -N(CH 3 ) 2 , -CH 2 N(CH 3 ) 2 , -SO 2 NH 2 , -OCHF 2 , -CF 3 and -OCF 3 .
- R ⁇ R 2 , R 3 and R 4 are independently hydrogen, halogen, -CN, -CF 3 , -NO 2 , -C(O)phenyl, lower alkyl or lower alkoxy, wherein phenyl optionally is substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, -CH 2 OH, -NO 2 , -CN, -C(O)OH, -O-lower alkyl, -C(O)OCH 3 , -C(O)NH 2 , -OCH 2 C(O)NH 2 , -NH 2 , -N(CH 3 ) 2 , -CH 2 N(CH 3 ) 2 , -SO 2 NH 2 , -OCHF 2 , -CF 3 and -OCF 3 .
- R 1 , R 2 , R 3 and R 4 are preferably independently hydrogen, halogen, -CF 3 , -NO 2 or -C(O)phenyl.
- R 1 to R 4 are hydrogen and one of them is different from hydrogen.
- one of R 1 to R 4 is halogen, especially chloro.
- R 3 is -NO 2 .
- R 1 to R 4 are hydrogen and the other two are different from hydrogen.
- R 1 and R 4 are both hydrogen and R 2 and R 3 are both halogen, especially chloro.
- R 1 and R 4 are both hydrogen and R 2 and R 3 are both -NO 2 .
- L is preferably a valence bond, -(CH 2 ) m S(CH 2 ) n -, -(CH 2 ) m S(O)(CH 2 ) n -, -(CH 2 ) m S(O) 2 (CH 2 ) n -, -(CH 2 ) m CHR 9 (CH 2 ) n -, -S(O) 2 (CH 2 ) m C(O)O(CH 2 ) n -, -S(O) 2 (CH 2 ) m C(O)(CH 2 ) n -, -S(O) 2 NR 9 (CH 2 ) m C(O)O(CH 2 ) n -, -S(O) 2 (CH 2 ) m OC(O)NR 9 (CH 2 ) n C(O)O(CH 2 ) r - or -S(O) 2 (CH 2 ) m CONR 9 (CH 2 )
- L is a valence bond, -S-, -S(O)-, -S(O) 2 (CH 2 ) n -, -S(O) 2 (CH 2 ) 2 C(O)O(CH 2 ) n -, -S(O) 2 (CH 2 ) 2 C(O)(CH 2 ) n -, -S(O) 2 (CH 2 ) 2 C(O)(CH 2 ) n -, -S(O) 2 NH(CH 2 ) 2 C(O)O(CH 2 ) n -, -S(O) 2 (CH 2 ) 4 OC(O)NH(CH 2 ) 2 C(O)O- or -S(O) 2 (CH 2 ) 2 CONH(CH 2 ) n -, wherein n is as defined for formula (I).
- L is preferably a valence bond, -S-, -S(O)-, -S(O) 2 -, -S(O) 2 CH 2 -, -S(O) 2 (CH 2 ) 2 -, -S(O) 2 (CH 2 ) 2 C(O)O-, -S(O) 2 (CH 2 ) 2 C(O)(CH 2 ) 2 -, -S(O) 2 NH(CH 2 ) 2 C(O)O-, -S(O) 2 (CH 2 ) 4 OC(O)NH(CH 2 ) 2 C(O)O- or -S(O) 2 (CH 2 ) 2 CONH(CH 2 ) 2 - and even more preferably L is -S(O) 2 CH 2 - or -S(O) 2 -.
- 5686.204-WO A is preferably lower alkyl, halogen, -CF 3 , -OH, -NO 2 , cycloalkyl, in which the cycloalkyl ring may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, -CH 2 OH, -NO 2 , -CN, -C(O)OH, -O-lower alkyl, -C(O)OCH 3 , -C(O)NH 2 , -OCH 2 C(O)NH 2 , -NH 2 , -N(CH 3 ) 2 ,
- R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 18a and R 19 are as defined for formula (I).
- A is lower alkyl, halogen, -CF 3 , -OH, cycloalkyl, in which the cycloalkyl ring may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, -CH 2 OH, -NO 2 , -CN, -C(O)OH, -O-lower alkyl, -C(O)OCH 3 , -C(O)NH 2 , -OCH 2 C(O)NH 2 , -NH 2 , -N(CH 3 ) 2 , -CH 2 N(CH 3 ) 2 , -SO 2 NH 2 , -OCHF 2 , -CF 3 and -OCF 3 ,
- R 1 to R are as defined for formula (I).
- R 12 and R 3 are independently selected from hydrogen and lower alkyl
- R 14 to R 18 are independently selected from hydrogen, lower alkyl, -NO 2 , halogen, -S(O) 2 R 21 , -CONR 21 R 22 , -OCHF 2 , -S(O) 2 NR 21 (CH) s C(O)OR 22 , wherein s is 1 or 2
- R 21 and R 22 are independently hydrogen, lower alkyl or pyridyl
- R 19 is hydrogen, lower alkyl or phenyl.
- A is lower alkyl, halogen, -CF 3 , -OH, cycloalkyl,
- R 14 is -S(O) 2 CH 3 , -CONH 2 , -CONH-pyridyl, -OCHF 2 or -S(O) 2 NH(CH) 2 C(O)OCH 3 .
- A is lower alkyl.
- M is a valence bond, -NH- or -N(CH 3 )-.
- B is preferably hydrogen, halogen, -CF 3 , -CF 2 CF 3 , lower alkyl, cycloalkyl, in which the cycloalkyl ring may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, -CH 2 OH, -NO 2 , -CN, -C(O)OH, -O-lower alkyl, -C(O)OCH 3 , -C(O)NH 2 , -OCH 2 C(O)NH 2 , -NH 2 , -N(CH 3 ) 2 , -CH 2 N(CH 3 ) 2 , -SO 2 NH 2 , -OCHF 2 , -CF 3 and -OCF 3 ,
- R 12 to R are as defined for formula (I).
- B is hydrogen, -CF 3 , lower alkyl, cycloalkyl, in which the cycloalkyl ring may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, -CH 2 OH, -NO 2 , -CN, -C(O)OH, -O-lower alkyl, -C(O)OCH 3 , -C(O)NH 2 , -OCH 2 C(O)NH 2 , -NH 2 , -N(CH 3 ) 2 , -CH 2 N(CH 3 ) 2 , -SO 2 NH 2 , -OCHF 2 , -CF 3 and -OCF 3 ,
- R 10 to R are as defined for formula (I).
- R 0 and R 11 are independently hydrogen, lower alkyl, halogen, -OCF 3 , -OCHF 2 , -CF 3 or -NO 2
- R 12 and R 13 are independently hydrogen, hydroxy or lower alkyl
- R 14 to R 18 are independently hydrogen, lower alkyl, halogen, -OCF 3 , -OCHF 2 , -CF 3 or -NO 2
- R 19 is hy- drogen or lower alkyl.
- B is hydrogen, -CF 3 , lower alkyl, cycloalkyl,
- B is -CF 3 or lower alkyl, and especially preferably B is lower alkyl.
- present compounds have the general formula (IV):
- M, B and R 14 are as defined for formula (I) or as defined in anyone of the preferred embodiments above.
- present compounds have the general formula (V):
- L is -S(CH 2 ) n -, -S(O)(CH 2 ) n - or -S(O) 2 (CH 2 ) n -, and n, A, M and B are as defined for formula (I) or as defined in anyone of the preferred embodiments above.
- M is a valence bond and B is -CF 3 or lower alkyl.
- M is -NR 9 -, wherein R 9 is hydrogen or lower alkyl and B is lower alkyl or
- R 14 is hydrogen, lower alkyl, halogen, -OCF 3 , -OCHF 2 , -CF 3 or -NO 2
- the present invention relates to a compound of the general formula (I'):
- R ⁇ R 2 , R 3 and R 4 independently are hydrogen, halogen, -CN, -CF 3 , -NO 2 , -OR 5 , lower alkyl, -SR 5 , -S(O) 2 NR 5 R 6 , -S(O)NR 5 R 6 , -S(O) 2 R 5 , -C(O)NR 5 R 6 , -CH 2 OR 5 , -CH 2 NR 5 R 6 or -C(O)OR 5 ;
- R 5 and R 6 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, het- eroaryl-lower alkenyl or heteroaryl-lower alkynyl; or R 5
- R 7 and R 8 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, het- eroaryl-lower alkenyl or heteroaryl-lower alkynyl; or R 7
- L and M independently are a valence bond, -(CH 2 ) m S(CH 2 ) n -, -(CH 2 ) m O(CH 2 ) n -,
- R 9 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl- lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocycly
- n and n independently are 0, 1 , 2 or 3;
- a and B independently are hydrogen, halogen, -CF 3 , -CF 2 CF 3 , -CN, -NO 2 , lower alkyl, lower alkenyl, lower alkynyl,
- G is -NR 19 -, -O- or -S-;
- K is -NR 20 -O- or -S-;
- R 10 , R 1 , R 2 , R 13 , R 4 , R 15 , R 16 , R 17 and R 18 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -OCF 2 CHF 2 , -NO 2 , -OR 21 , -NR 21 R 22 , lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl- lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl
- R 21 and R 22 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, het- eroaryl-lower alkenyl or heteroaryl-lower alkynyl; or R 21
- R 19 and R 20 independently are hydrogen, -OR 23 , -NR 23 R 24 , lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower
- R 23 and R 24 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloal- kenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower
- M represents a group wherein n is 0, B is not halogen, -CN or -NO 2 ;
- the invention relates to a compound of the general formula (IT):
- R ⁇ R 2 , R 3 , R 4 , L, M, A and B are as defined for formula (I').
- R ⁇ R 2 , R 3 and R 4 are independently hydrogen, halogen, -CN, -CF 3 , -NO 2 , lower alkyl, lower alkoxy, -S(O) 2 NR 5 R 6 , -S(O)NR 5 R 6 , -S(O) 2 R 5 , -C(O)NR 5 R 6 or -C(O)OR 5 , wherein R 5 and R 6 are as defined for formula (I').
- R ⁇ R 2 , R 3 and R 4 are independently hydrogen, halogen, -CN, -CF 3 or -S(O) 2 R 5 , wherein R 5 is as defined for formula (I').
- R , R 2 , R 3 and R 4 are independently hydrogen, halogen, -CN, -CF 3 , lower alkyl, lower alkoxy or -C(O)NR 5 R 6 , wherein R 5 and R 6 independently are hydrogen or lower alkyl.
- R 1 , R 2 , R 3 and R 4 are preferably independently hydrogen, halogen, -CN, lower alkyl or lower alkoxy.
- two of the groups R 1 to R 4 are hydrogen and the other two are different from hydrogen.
- R 1 and R 4 are both hydrogen and R 2 and R 3 are as defined for formula (I') or as defined in the above preferred embodiments thereof.
- R 2 and R 3 are both halogen.
- L is a valence bond, -(CH 2 ) m S(CH 2 ) n -,
- Still more preferred L is a valence bond, -CH 2 -, -CH 2 S-, -S-, -S(O)- or -S(O) 2 -.
- L is -S-, -S(O)- or -S(O) 2 -.
- A is lower alkyl, halogen
- R 10 , R , R 14 , R 15 , R 16 , R 17 , R 8 and R 19 are as defined for formula (I').
- R 10 , R 1 , R 14 , R 15 , R 6 , R 17 , R 8 and R 19 are preferably independently selected from hydrogen, halogen, lower alkyl, -NH 2 , -CF 3 ,-CN, -S-(cycloalkyl-lower aikyl),-NHC(O)(cycloalkyl-lower alkyl), -C(O)NH 2 , -S-lower alkyl, -O-lower alkyl, phenyl, furanyl, thienyl, -NHC(O)O-lower alkyl and -C(O)CH 3 .
- R 19 is preferably lower alkyl or hydrogen.
- More preferred A is lower alkyl
- R 17 and R 19 are as defined for formula (I) or in the above preferred embodiments thereof.
- R 17 is preferably lower alkyl, -NH 2 or -S-lower alkyl and R 19 is preferably hydrogen.
- B is hydrogen, halogen, -CF 3 , -CF 2 CF 3 , lower alkyl,
- R 10 to R 20 are as defined for formula (I').
- R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 8 are preferably independently selected from hydrogen, halogen, lower alkyl, -NH 2 , -CF 3 ,-CN, -S-(cycloalkyl-lower alkyl), -NHC(O)(cycloalkyl-lower alkyl), -C(O)NH 2 , -S-lower alkyl, -O-lower alkyl, phenyl, furanyl, thienyl, -NHC(O)O-lower alkyl and -C(O)CH 3 .
- R 19 and R 20 are preferably independently selected from lower alkyl and hydrogen.
- More preferred B is -CF 3 or lower alkyl. 5686.204-WO
- the invention relates to a compound of the formula (IT) as defined above wherein R 2 and R 3 are both either halogen, -CN or -CF 3 , L is -S(CH 2 ) n -, -S(O)(CH 2 ) n - or -S(O) 2 (CH 2 ) n - wherein n is 0, 1 , 2 or 3, and R ⁇ R 4 , A, M and B are as defined for formula (I') or as defined in the above preferred embodiments thereof.
- the invention in another aspect relates to a compound of the formula (II') as defined above wherein L is -S(CH 2 ) n -, -S(O)(CH 2 ) n - or -S(O) 2 (CH 2 ) n -, wherein n is 0, 1 , 2 or 3, M is a valence bond, B is -CF 3 or isopropyl, and R ⁇ R 2 , R 3 , R 4 and A are as defined for formula (III') or as defined in the above preferred embodiments thereof, with the proviso that when R 1 , R 2 , R 3 and R 4 are hydrogen, B is isopropyl and L is -SCH 2 -, A must not be hydrogen.
- the invention relates to a compound of the formula (IT) as defined above wherein L is -S(CH 2 ) n -, -S(O)(CH 2 ) n - or -S(O) 2 (CH 2 ) n -, wherein n is 0, 1 , 2 or 3, at least one of the groups R 2 and R 3 are -CN, and R 1 , R 4 , A, M and B are as defined for formula (I') or as defined in the above preferred embodiments thereof.
- the invention relates to a compound of the formula (II') as defined above wherein L is -S(CH 2 ) n -, -S(O)(CH 2 ) n - or -S(O) 2 (CH 2 ) n -, wherein n is 0, 1 , 2 or 3, R 1 , R 2 , R 3 and R 4 are as defined for formula (I), A is a heterocyclic ring, and
- M is a valence bond
- B is -CF 3 , -CN, lower alkyl, lower alkenyl, lower alkynyl or halogen.
- the invention relates to a compound of an EC 50 value as determined by the method for determining the ability to stimulate cAMP formation in a cell line expressing the cloned human GLP-1 receptor disclosed herein of less than 25 ⁇ M and having the general formula (III'):
- R ⁇ R 2 , R 3 and R 4 independently are hydrogen, halogen, -CN, -CF 3 , -NO 2 , -OR 5 , -NR 5 R 6 , lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocyclyl, heteroaryl, -SR 5 , -NR 5 S(O) 2 R 6 , -S(O) 2 NR 5 R 6 , -S(O)NR 5 R 6 , -S(O) 2 R 5 , -C(O)NR 5 R 6 , -CH 2 OR 5 , -CH 2 NR 5 R 6 or -C(O)OR 5 ;
- R 5 and R 6 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, het- eroaryl-lower alkenyl or heteroaryl-lower alkynyl; or R 5
- D is hydrogen, halogen, -CN, -CF 3 , -NO 2 , -OR 7 , -NR 7 R 8 , lower alkyl, aryl, -C(O)NR 7 R 8 , -CH 2 OR 7 , -CH 2 NR 7 R 8 or -C(O)OR 7 ;
- R 7 and R 8 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, het- eroaryl-lower alkenyl or heteroaryl-lower alkynyl; or R 7
- R 9 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl- lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocycly
- n and n independently are 0, 1 , 2 or 3;
- a and B independently are hydrogen, halogen, -CF 3 , -CF 2 CF 3 , -CN, -NO 2 , lower alkyl, lower alkenyl, lower alkynyl,
- p 1, 2 or 3;
- G is -NR 19 -, -O- or -S-;
- R 10 , R 11 , R 2 , R 13 , R 14 , R 5 , R 16 , R 17 and R 18 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -OCF 2 CHF 2 , -NO 2 , -OR 21 , -NR 21 R 22 , lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl- lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl
- R 21 and R 22 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, het- eroaryl-lower alkenyl or heteroaryl-lower alkynyl; or R 21
- R 19 and R 20 independently are hydrogen, -OR 23 , -NR 23 R 24 , lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower
- R 23 and R 24 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloal- kenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower
- M represents a group wherein n is 0, B is not halogen, -CF 3 , -CN or -NO 2 ;
- the cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl ring systems defined in the above formulae (I'), (II') and (III') may optionally be substituted by one or more substituents, for example selected from the group consisting of halogen, lower alkyl, lower alkanoyl such as formyl, acetyl, propionyl, butyryl, valeryl, hexanoyl and the like, -OH, -CH 2 OH, -NO 2 , -CN, -CO 2 H, -O-lower alkyl, aryl-lower alkyl, -CO 2 CH 3 , -CONH 2 , -OCH 2 CONH 2 , -NH 2 , -N(CH 3 ) 2 , -CH 2 N(CH 3 ) 2 , -SO 2 NH 2 , -OCHF 2 , -CF 3 , -OCF 3
- the substituents may be the same or different.
- the above ring systems may also be substituted by two substituents forming a bridge, for example -OCH 2 O- or -OCH 2 CH 2 O-.
- the compounds according to the invention are preferably characterised by having a molecular weight of up to 1000, preferably of up to 600.
- the compounds according to the invention have an EC 50 value as determined by the method for determining the ability to stimulate cAMP formation in a cell line expressing the cloned human GLP-1 receptor disclosed in the following of less than 25 ⁇ M, such as of less than 10 ⁇ M, more preferred of less than 2 ⁇ M and even more preferred of less than 1 ⁇ M.
- the invention relates to a non-peptide GLP-1 agonist which activates the human GLP-1 receptor.
- Agonist activity may eg be determined by the assays described in example 172.
- Compounds may also be shown to be active by measuring insulin release from isolated human islets. This can be done according to the method disclosed in Eizirik DL, Korbutt GS, Hellerstr ⁇ m C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J. Clin. Invest. 90:1263-1268, 1992.
- non-peptide GLP-1 agonist activates the human GLP-1 receptor without competing with GLP-1 in a competition binding assay.
- This may be determined by measuring a compound that behaves as an agonist in the assays described in example 172 in a standard receptor binding assay.
- Plasma membranes may be used prepared as in example 172. Binding assays may be carried out in polypropylene tube. The buffer may be 25 mM HEPES, 0.1% BSA, pH 7.4. GLP-1 and test compounds may be dissolved and diluted as described in Example 172. Tracer (labelled GLP-1 ) may be prepared as described in (28). Tracer (30.000 cpm) + plasma membrane (0.5-2 ⁇ g) may be mixed with test compound and incubated at 37 °C for 1 hour. Non-specific binding may be determined with 10 "7 M GLP-1. Bound and unbound tracer may be separated by vacuum filtration.
- the filters can be counted in a ⁇ -scintillation counter.
- the binding of the tracer in the absence of the test compounds and GLP-1 is set to 100%.
- a compound which does not compete with GLP-1 in a competition binding assay will not displace the tracer. Therefore, the tracer will display an un- changed binding of 100% in this assay whereas different concentrations of GLP-1 will compete with the tracer resulting in a decreased binding of the tracer in the range of between 0 and up to 100%.
- non-peptide GLP-1 agonist potentiates the binding of GLP-1 to the human GLP-1 receptor in a competition binding assay.
- non-peptide GLP-1 agonist stabilises an active conformation of the human GLP-1 receptor different from the one(s) which GLP-1 stabilises.
- This may be determined eg by performing a saturation experiment determining the affinity of GLP-1 with and without the presence of the compound in question.
- the saturation experiment is a standard receptor pharmacology experiment whereby the true affinity of a compound for a receptor can be measured (32).
- the protocol for the binding assay described above may be used except for that here the tracer is diluted and two sets of samples are measured, one with 10 "6 M GLP-1 added (to determine non-specific binding) and one without (to determine total binding). The specific binding (total minus non-specific) is then plotted vs the concentration of tracer added.
- a curve fitting program eg the saturation/scatchard template in GraphPad Prism® may then determine the number of binding sites and the affinity.
- non-peptide GLP-1 agonists according to the invention may be either partial or full agonists.
- non-peptide GLP-1 agonist is a partial agonist.
- Such partial agonists may be less likely of causing the receptor to desensitise because they do not fully activate the receptor and therefore also do not fully activate the desensitisation signals.
- the non-peptide partial agonists have an E max of less than 90%, preferably less than 80% and more preferred in the range of 35 to 75% of that of GLP-1.
- the non-peptide GLP-1 agonist is a full agonist.
- the non-peptide GLP-1 agonist has at least a 10 fold selectivity towards the human GLP-1 receptor compared to the human glucagon receptor and/or the human GIP receptor. This may be determined eg by the assays described in example 172 using cells expressing the human glucagon receptor and/or the human GIP receptor and comparing the formation of cAMP with the amount obtained using the cells expressing the human GLP-1 receptor.
- the agonistic effect mediated by the non-peptide GLP-1 agonists can be antagonised by a GLP-1 antagonist.
- GLP-1 antagonist 6-(2,5-dichlorobenzyl)-1 -hydroxy-2-[2-(4- morpholinyl)ethyl]-1 ,6-dihydropyrrolo[3',4'5,6]pyrido[3,4-b]indol-3(2H)-one.
- 6-(2,5-Dichlorobenzyl)-1-hydroxy-2-[2-(4-morpholinyl)ethyl]-1 ,6-dihydropyrrolo[3',4'5,6]- pyrido[3,4-b]indol-3(2H)-one may be prepared according to the method below:
- 6-(2,5-Dichlorobenzyl)-1-hydroxy-2-[2-(4-morpholinyl)ethyl]-1 ,6-dihydropyrrolo[3',4',5,6]- pyrido[3,4-b]indol-3(2H)-one was prepared by a slight modification of a reported procedure (Dodd et al., J Org. Chem.
- the non-peptide agonists may activate the human receptor both in the absence of GLP-1 and in the presence of GLP-1 but only activate the rat GLP-1 receptor in the presence of GLP-1.
- the compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included within the scope of the invention.
- geometric isomers may be formed. It is intended that any geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.
- the present invention also encompasses pharmaceutically acceptable salts of the present compounds.
- Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
- Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
- suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane- sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like.
- compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
- metal salts include lithium, sodium, potassium, magnesium salts and the like.
- ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
- Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form.
- the acid addition salts may be obtained as the direct products of compound synthesis.
- the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
- the compounds of the present invention may form solvates with standard low molecular weight solvents using methods well known to the person skilled in the art. Such solvates are also contemplated as being within the scope of the present invention.
- the invention also encompasses prodrugs of the present compounds which on administration undergo chemical conversion by metabolic processes before becoming active pharma- cological substances.
- prodrugs will be functional derivatives of the compounds of the general formula (I) which are readily convertible in vivo into the required compound of the formula (I).
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bund- gaard, Elsevier, 1985.
- the invention also encompasses active metabolites of the present compounds.
- the compounds according to the present invention activate the human GLP-1 receptor and are accordingly useful for the treatment and/or prevention of disorders and diseases in which such an activation is beneficial.
- the invention relates to a compound according to the invention for use as a medicament.
- the invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound according to the invention together with one or more pharmaceutically acceptable carriers or excipients.
- the invention relates to the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of a disorder or disease wherein an activation of the human GLP-1 receptor is beneficial.
- the invention also relates to a method for the treatment and/or prevention of disorders or diseases wherein an activation of the human GLP-1 receptor is beneficial the method com- prising administering to a subject in need thereof an effective amount of a compound according to the invention.
- the present compounds to activate the human GLP-1 receptor are useful for the treatment and/or prevention of disorders and diseases, such as metabolic disorders, wherein an activation of the said receptor is beneficial. Accordingly, they may find use in the treatment and/or prevention of hyperglycaemia, dyslipidemia, Type 1 diabetes, Type 2 diabetes, hypertriglyceridemia, syndrome X, insulin resistance, IGT, obesity, diabetes as a consequence of obesity, diabetic dyslipidemia, hyperlipidemia, cardiovascular diseases and hypertension. Furthermore, they may find use in the treatment and/or prevention of appetite regulation and energy expenditure disorders such as eating disorders eg bulimia, and other conditions where a weight reduction is required. They may also find use in the treatment and/or prevention of anxiety, movement disorder, aggression, psychosis, seizures, panic attacks, hysteria or sleep disorders. A further application is for the inhibition of intesti- nal motility.
- the present compounds are used for the manufacture of a medicament for the treatment and/or prevention of hyperglycemia.
- the present compounds are used for the manufacture of a medicament for lowering blood glucose in a mammal.
- the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of IGT.
- the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of Type 2 diabetes.
- the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from IGT to Type 2 diabetes. In yet another preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.
- the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of Type 1 diabetes.
- Such treatment and/or prevention is normally accompanied by insulin therapy.
- the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of obesity.
- the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of an appetite regulation or energy expenditure disorder.
- the present compounds may be administered in combination with one or more further pharmacologically active substances eg selected from antidiabetics, antiobesity agents, antihypertensive agents and agents for the treatment and/or prevention of complications resulting from or associated with diabetes.
- pharmacologically active substances eg selected from antidiabetics, antiobesity agents, antihypertensive agents and agents for the treatment and/or prevention of complications resulting from or associated with diabetes.
- Suitable antidiabetics comprise insulin, GLP-1 derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S which is incorporated herein by reference as well as orally active hypoglycaemic agents.
- the orally active hypoglycaemic agents preferably comprise sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Alanex Corporation, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, insulin sensitizers, DPP-IV inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents, compounds lowering food intake, PPAR and RXR agonists and agents acting on the ATP-dependent potassium channel of the ⁇ -cells.
- the present compounds are administered in combination
- the present compounds are administered in combination with a sulphonylurea eg tolbutamide, glibenclamide, glipizide or giicazide.
- a sulphonylurea eg tolbutamide, glibenclamide, glipizide or giicazide.
- the present compounds are administered in combination with a biguanide eg metformin.
- the present compounds are administered in combination with a meglitinide eg repaglinide.
- the present compounds are administered in combination with a thiazolidinedione eg troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 to Dr. Reddy's Research Foundation.
- a thiazolidinedione eg troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 to Dr. Reddy's Research Foundation.
- the present compounds may be administered in combination with the insulin sensitizers disclosed in WO 99/19313 to Dr. Reddy's Research Foundation.
- the present compounds are administered in combination with an ⁇ -glucosidase inhibitor eg miglitol or acarbose.
- an ⁇ -glucosidase inhibitor eg miglitol or acarbose.
- the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the ⁇ -cells eg tolbutamide, glibenclamide, glipizide, giicazide or repaglinide.
- an agent acting on the ATP-dependent potassium channel of the ⁇ -cells eg tolbutamide, glibenclamide, glipizide, giicazide or repaglinide.
- the present compounds may be administered in combination with nateglinide.
- the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent eg cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
- an antihyperlipidemic agent or antilipidemic agent eg cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
- the present compounds are administered in combination with more than one of the above-mentioned compounds eg in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
- the compounds according to the invention may be administered in combination with one or more antiobesity agents or appetite regulating agents.
- Such agents may be selected from the group consisting of CART agonists, NPY antagonists, MC4 agonists, orexin antagonists, H3 antagonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, ⁇ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK agonists, serotonin re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR ⁇ agonists.
- the antiobesity agent is leptin.
- the antiobesity agent is dexamphetamine or amphetamine.
- the antiobesity agent is fenfluramine or dexfenfluramine.
- the antiobesity agent is sibutramine.
- the antiobesity agent is orlistat.
- the antiobesity agent is mazindol or phentermine.
- the present compounds may be administered in combination with one or more antihypertensive agents.
- antihypertensive agents are ⁇ -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, 5686.204-WO isradipine, nimodipine, diltiazem and verapamil, and ⁇ -blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19 th Edition, Gennaro
- the compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
- the pharmaceutical compositions according to the invention may be formulated with pharmaceutically ac- ceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy,19 th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
- compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublin- gual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
- compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well-known in the art.
- Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
- Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot in- jectable formulations are also contemplated as being within the scope of the present invention.
- Suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.
- a typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages.
- the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
- a typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain of from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg.
- parenteral routes such as intravenous, intrathecal, intramuscular and similar administra- tion
- typically doses are in the order of about half the dose employed for oral administration.
- the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
- One example is an acid addition salt of a compound having the utility of a free base.
- a compound of the formula (I) contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the formula (I) with a chemical equivalent of a pharmaceutically acceptable acid, for example, inorganic and organic acids. Representative examples are mentioned above.
- Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion.
- solutions of the novel compounds of the formula (I) in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed.
- aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
- Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
- solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose.
- liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water.
- the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- compositions formed by combining the novel compounds of the formula (I) and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
- the formulations may conveniently be presented in unit dosage form by meth- ods known in the art of pharmacy.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
- the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge.
- the amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
- the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
- a typical tablet which may be prepared by conventional tabletting techniques may contain:
- Active compound (as free compound or salt thereof) 5.0 mg Lactosum Ph. Eur. 67.8 mg
- the pharmaceutical composition of the invention may comprise the compound of the formula (I) in combination with further pharmacologically active substances such as those described in the foregoing.
- R 1 to R 4 are as defined for formula (I) and R represents CF 3 , C 1- ⁇ -alkyl, phenyl, phenyl-C 1-6 -alkyl or 2-furanyl.
- STEP 2 A mixture of 3,6-dichloro-2-methoxyquinoxaline (50 mg, 0.218 mmol), potassium carbonate (31 mg, 0.224 mmol) and 2-mercapto-5-methylthiadiazole (31 mg, 0.219 mmol) in 3 ml of acetone was stirred while adding caesium fluoride (40 mg, 0.262 mmol) and two drops of DMF. The mixture was stirred and heated at 55 °C for 16 hours. The cooled mixture was filtered and washed with acetone. The organic solution was evaporated and the residue was crystallised from methanol to afford 13 mg (18%) of the title compound as off white crystals.
- EXAMPLE 32 1 H NMR (CDCI 3 ): ⁇ 1.5 (t, 3H), 3.6 (s, 3H), 4.5 (q, 2H), 8.2 (s, 1 H), 8.4 (s, 1 H); MS (APCI positive) 365.
- EXAMPLE 33 6,7-Dichloro-2-methyl-3-(isobutyl-1-sulfonyl)quinoxaline
- the crude alkylation product was dissolved in 1 ,2-dichloroethane (5 ml), then mCPBA (574 mg, 1.32 mmol) was added and the mixture was stirred at room temperature overnight.
- the reaction mixture was quenched by addition of a saturated solution of sodium bicarbonate.
- the layers were separated and the aqueous layer was extracted twice with 1 ,2- dichloroethane.
- the product was purified by flash column chromatography using ethyl ace- tate:hexane 1 :5.
- the crude alkylation product was dissolved in 1 ,2- dichloroethane to which was added mCPBA (1.1 g, 1.3 mmol). The oxidation reaction was stirred at room temperature overnight. The reaction was quenched by addition of a saturated solution of sodium bicarbonate. The layers were separated and the aqueous layer was extracted twice with 1 ,2-dichloroethane. The combined organic layers were concentrated under reduced pressure to a pale yellow solid. The product was purified by HPLC.
- the title compound was prepared using the first step of example 24.
- the title compound was prepared according example 18 using 1-phenyl-1 H-tetrazole-5-thiol.
- the compound was prepared using the same procedure as described for example 57 using ethanol amine instead of propargylamine.
- reaction mixture was stirred overnight at room temperature.
- the reaction was quenched by addition of a saturated solution of sodium bicarbonate. After separating the layers, the aqueous layer was extracted twice with ethyl acetate. The organic layers were combined and concentrated under reduced pressure yielding a white solid. This solid was further purified by column chromotography affording two components as a white solid.
- EXAMPLE 68 1 H NMR (CDCI 3 ): ⁇ 1.43 (d, 6H), 3.51 (s, 3H), 4.10 (m, 1 H), 8.20 (s, 1 H), 8.28 (s, 1 H); MS (APCI positive) 319.
- EXAMPLE 69 1 H NMR (CDCI 3 ): ⁇ 1.41 (d, 3H), 1.45 (d, 3H), 3.01 (s, 3H), 3.75 (m, 1 H), 8.27 (s, 1 H), 8.34 (s, 1 H); MS (APCI positive) 303.
- the title compound was prepared using the same procedure as described in example 7.
- the sulfide was prepared as described in example 12 and oxidised with mCPBA.
- a white solid was isolated and purified by column chromatography (ethyl acetate:petroleum ether 30:70).
- STEP 2 The title compound was then prepared from the compound prepared in step 1 using the same procedure as described in example 19. 41 % yield of a yellow solid was isolated and purified by column chromatography (ethyl acetate: petroleum ether 10:90).
- step 1 the following compound was made:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00900499A EP1147094A1 (en) | 1999-01-15 | 2000-01-14 | Non-peptide glp-1 agonists |
JP2000593594A JP2002534512A (en) | 1999-01-15 | 2000-01-14 | Non-peptide GLP-1 agonist |
AU30335/00A AU3033500A (en) | 1999-01-15 | 2000-01-14 | Non-peptide glp-1 agonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199900041 | 1999-01-15 | ||
DKPA199900041 | 1999-01-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000042026A1 true WO2000042026A1 (en) | 2000-07-20 |
WO2000042026B1 WO2000042026B1 (en) | 2000-10-05 |
Family
ID=8089073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2000/000014 WO2000042026A1 (en) | 1999-01-15 | 2000-01-14 | Non-peptide glp-1 agonists |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1147094A1 (en) |
JP (1) | JP2002534512A (en) |
AU (1) | AU3033500A (en) |
WO (1) | WO2000042026A1 (en) |
Cited By (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003031432A1 (en) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
WO2003084563A1 (en) * | 2002-04-04 | 2003-10-16 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
EP1372654A2 (en) * | 2001-04-06 | 2004-01-02 | SmithKline Beecham Corporation | Quinoline inhibitors of hyak1 and hyak3 kinases |
WO2004002481A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
WO2004052371A2 (en) * | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Cyclic quinoline compounds for use in mch receptor related disorders |
US6770620B2 (en) | 2000-09-18 | 2004-08-03 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
WO2005023291A2 (en) * | 2003-09-11 | 2005-03-17 | Novo Nordisk A/S | Use of glp1-agonists in the treatment of patients with type i diabetes |
WO2005026125A1 (en) * | 2003-09-12 | 2005-03-24 | Glaxo Group Limited | Quinoline compounds and pharmaceutical compositions containing them |
WO2005030797A2 (en) | 2003-09-30 | 2005-04-07 | Novo Nordisk A/S | Melanocortin receptor agonists |
WO2005067932A1 (en) * | 2004-01-06 | 2005-07-28 | Janssen Pharmaceutica, N.V. | (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity |
WO2006003096A1 (en) * | 2004-07-02 | 2006-01-12 | Novo Nordisk A/S | Condensed thiophene derivatives and their use as cyclic glp-1 agonists |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
WO2006053906A1 (en) | 2004-11-22 | 2006-05-26 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
WO2006058923A1 (en) | 2004-12-03 | 2006-06-08 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
WO2006072881A1 (en) | 2005-01-10 | 2006-07-13 | Cortendo Invest Ab | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
WO2006082204A1 (en) | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
WO2007006814A1 (en) | 2005-07-14 | 2007-01-18 | Novo Nordisk A/S | Urea glucokinase activators |
WO2007015805A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | 1-amino linked compounds |
WO2007110364A1 (en) | 2006-03-28 | 2007-10-04 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine h3 receptor activity |
WO2007137968A1 (en) | 2006-05-29 | 2007-12-06 | High Point Pharmaceuticals, Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
US7348340B2 (en) | 2000-11-06 | 2008-03-25 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
WO2008059025A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
WO2008084044A1 (en) | 2007-01-11 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
EP1956004A1 (en) | 2002-03-27 | 2008-08-13 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
EP1956020A2 (en) | 2001-05-05 | 2008-08-13 | Smithkline Beecham Plc | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity |
US7501416B2 (en) | 2004-02-06 | 2009-03-10 | Bristol-Myers Squibb Company | Quinoxaline compounds and methods of using them |
US7576215B2 (en) | 2003-12-12 | 2009-08-18 | Wyeth | Quinolines and pharmaceutical compositions thereof |
WO2009127321A1 (en) | 2008-04-18 | 2009-10-22 | Merck Patent Gmbh, | Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
EP2226324A1 (en) | 2001-07-06 | 2010-09-08 | Merck Sharp & Dohme Corp. | Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines for use in the treatment of diabetes type ii |
WO2010102811A1 (en) * | 2009-03-12 | 2010-09-16 | Grünenthal GmbH | Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators |
EP2233470A1 (en) | 2005-07-04 | 2010-09-29 | High Point Pharmaceuticals, LLC | Histamine H3 receptor antagonists |
WO2010114824A1 (en) | 2009-03-30 | 2010-10-07 | Transtech Pharma Inc | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
US7816492B2 (en) | 1998-11-20 | 2010-10-19 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors |
EP2262364A2 (en) * | 2008-03-07 | 2010-12-22 | TransTech Pharma, Inc | Oxadiazoanthracene compounds for the treatment of diabetes |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
USRE42190E1 (en) | 1998-11-20 | 2011-03-01 | Arena Pharmaceuticals, Inc. | Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors |
EP2292653A1 (en) | 2005-02-02 | 2011-03-09 | Novo Nordisk A/S | Novel insulin derivatives |
EP2298337A2 (en) | 2003-12-09 | 2011-03-23 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
US7919528B2 (en) | 2002-05-31 | 2011-04-05 | Glaxosmithkline Llc | Peptide deformylase inhibitors |
WO2011048614A2 (en) | 2009-10-22 | 2011-04-28 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
EP2316446A1 (en) | 2004-06-11 | 2011-05-04 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
WO2011058193A1 (en) | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
EP2329839A1 (en) | 2002-01-10 | 2011-06-08 | Imperial Innovations Limited | Modification of feeding behavior by GLP-1 and PYY |
US7964732B2 (en) | 2006-11-17 | 2011-06-21 | Pfizer Inc. | Substituted bicyclocarboxyamide compounds |
WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
WO2011104379A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
WO2011117416A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
EP2371378A1 (en) | 2003-01-10 | 2011-10-05 | Imperial Innovations Limited | Modification of feeding behaviour and weight control by oxyntomodulin |
WO2011135376A1 (en) | 2010-04-30 | 2011-11-03 | Astex Therapeutics Limited | Pyrazolyl quinazoline kinase inhibitors |
US8097452B2 (en) | 1998-11-20 | 2012-01-17 | Arena Pharmaceuticals, Inc. | Human orphan G protein-coupled receptors |
US8101576B2 (en) | 2006-12-13 | 2012-01-24 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
EP2444397A1 (en) | 2004-01-06 | 2012-04-25 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
US8178684B2 (en) | 2009-03-12 | 2012-05-15 | Gruenenthal Gmbh | Substituted nicotinamides as KCNQ2/3 modulators |
US8207342B2 (en) | 2009-03-10 | 2012-06-26 | Gruenenthal Gmbh | Substituted 3-amino-2-mercaptoquinolines as KCNQ2/3 modulators |
US8217001B2 (en) | 2001-09-24 | 2012-07-10 | Imperial Innovations Limited | Modification of feeding behavior |
US8247573B2 (en) | 2009-03-12 | 2012-08-21 | Gruenenthal Gmbh | Substituted N-(2-mercaptopyridin-3-yl)amides as KCNQ2/3 modulators |
US8269011B2 (en) | 2007-06-06 | 2012-09-18 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
WO2012130866A1 (en) | 2011-03-28 | 2012-10-04 | Novo Nordisk A/S | Novel glucagon analogues |
US8304546B2 (en) | 2008-12-05 | 2012-11-06 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2012177443A3 (en) * | 2011-06-22 | 2013-04-25 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
WO2013061074A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | Quinolines as fgfr kinase modulators |
WO2013061081A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | Anticancer benzopyrazines via the inhibition of fgfr kinases |
WO2013061077A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | New compounds |
WO2013061080A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | Anticancer pyridopyrazines via the inhibition of fgfr kinases |
WO2013069765A1 (en) | 2011-11-09 | 2013-05-16 | 協和発酵キリン株式会社 | Nitrogenated heterocyclic compound |
US8470852B2 (en) | 2010-08-27 | 2013-06-25 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators |
US8513282B2 (en) | 2008-10-23 | 2013-08-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8541368B2 (en) | 2011-09-23 | 2013-09-24 | Novo Nordisk A/S | Glucagon analogues |
US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
WO2013155600A1 (en) | 2012-04-16 | 2013-10-24 | Kaneq Pharma | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
US8618129B2 (en) | 2010-09-01 | 2013-12-31 | Gruenenthal Gmbh | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
US8653101B2 (en) | 2010-08-27 | 2014-02-18 | Gruenenthal Gmbh | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
US8653102B2 (en) | 2010-08-27 | 2014-02-18 | Gruenenthal Gmbh | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators |
US8669228B2 (en) | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
US8673908B2 (en) | 2008-11-10 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd. | Kynurenine production inhibitor |
WO2014045266A1 (en) | 2012-09-24 | 2014-03-27 | Ulf Eriksson | Treatment of type 2 diabetes and related conditions |
US8697875B2 (en) | 2008-12-23 | 2014-04-15 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
WO2014121885A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4 |
CN104024257A (en) * | 2011-10-04 | 2014-09-03 | 吉利德卡利斯托加有限责任公司 | Novel quinoxaline inhibitors of PI3K |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
US8900593B2 (en) | 2007-02-15 | 2014-12-02 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US8981047B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Glucagon antagonists |
US9018164B2 (en) | 2005-11-07 | 2015-04-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
WO2015144803A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9150569B2 (en) | 2010-05-10 | 2015-10-06 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine |
WO2015160678A1 (en) | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Sitagliptin tannate complex |
US9168288B2 (en) | 2010-04-09 | 2015-10-27 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist |
US9198906B2 (en) | 2006-10-02 | 2015-12-01 | Cortendo Ab (Publ) | Ketoconazole enantiomer in humans |
US9241942B2 (en) | 2007-06-08 | 2016-01-26 | Mannkind Corporation | IRE-1α inhibitors |
US9249206B2 (en) | 2010-12-22 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
DE102014112747A1 (en) | 2014-09-04 | 2016-03-10 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Use of a quinoxaline derivative in an imaging process |
US9290478B2 (en) | 2010-11-29 | 2016-03-22 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US9296701B2 (en) | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9303030B2 (en) | 2012-05-30 | 2016-04-05 | Astex Therapeutics Limited | Compounds |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9340557B2 (en) | 2013-03-12 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9447098B2 (en) | 2012-05-30 | 2016-09-20 | Astex Therapeutics Ltd | Pteridines as FGFR inhibitors |
US9474790B2 (en) | 2013-04-18 | 2016-10-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
US9493426B2 (en) | 2013-04-26 | 2016-11-15 | Astex Therapeutics Limited | Quinazolinone derivatives useful as FGFR kinase modulators |
WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9790232B2 (en) | 2013-11-01 | 2017-10-17 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9808455B2 (en) | 2007-12-12 | 2017-11-07 | Axovant Sciences Gmbh | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US9867869B2 (en) | 2012-12-12 | 2018-01-16 | Massachusetts Institute Of Technology | Insulin derivatives for diabetes treatment |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US10039761B2 (en) | 2013-10-17 | 2018-08-07 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
WO2018167194A1 (en) | 2017-03-15 | 2018-09-20 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
US10085982B2 (en) | 2014-03-26 | 2018-10-02 | Astex Therapeutics Ltd | Combinations |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2019217165A1 (en) * | 2018-05-08 | 2019-11-14 | Vtv Therapeutics Llc | Therapeutic uses of glp1r agonists |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
WO2019219714A1 (en) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
WO2020074958A1 (en) | 2018-10-12 | 2020-04-16 | Strongbridge Dublin Limited | Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism |
US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
US10766907B2 (en) | 2016-09-08 | 2020-09-08 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10898482B2 (en) | 2015-02-10 | 2021-01-26 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
EP3318561B1 (en) * | 2010-05-26 | 2021-12-22 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
US11542247B2 (en) | 2015-09-23 | 2023-01-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2262789A1 (en) * | 2008-03-05 | 2010-12-22 | F. Hoffmann-La Roche AG | 2-aminoquinolines |
EP2396004A4 (en) * | 2009-02-11 | 2012-07-25 | Reaction Biology Corp | Selective kinase inhibitors |
JP5696856B2 (en) | 2009-09-03 | 2015-04-08 | バイオエナジェニックス | Heterocyclic compounds for inhibition of PASK |
EP2681207B1 (en) * | 2011-03-02 | 2016-12-28 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
US10045981B2 (en) | 2015-11-24 | 2018-08-14 | Jakpharm, Llc | Selective kinase inhibitors |
WO2019103060A1 (en) * | 2017-11-22 | 2019-05-31 | 第一三共株式会社 | Condensed tricyclic compound |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB966818A (en) * | 1960-01-14 | 1964-08-19 | Bayer Ag | 2-halo-3-mercapto-quinoxaline substitution products and process for their production |
EP0018493A1 (en) * | 1979-04-05 | 1980-11-12 | Bayer Ag | 2-Sulfonyl-quinoxalines, processes for their preparation and their use as microbicides |
EP0216299A1 (en) * | 1985-09-21 | 1987-04-01 | BASF Aktiengesellschaft | Quinoxaline derivatives, method for their preparartion and their use to protect cultivated plants against phytotoxical reaction of herbicides |
EP0338346A2 (en) * | 1988-04-11 | 1989-10-25 | Nisshin Flour Milling Co., Ltd. | Quinoxaline derivatives and antiulcer agents |
WO1995024403A1 (en) * | 1994-03-10 | 1995-09-14 | Zeneca Limited | (4,4-difluorobut-3-enylthio)-substituted heterocyclic or carbocyclic ring compounds having pesticidal activity |
WO1996030370A2 (en) * | 1995-03-27 | 1996-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole and thiadiazole derivatives, their preparation and pharmaceutical compositions useful in the treatment of thrombocytopenia |
WO1997032858A1 (en) * | 1996-03-05 | 1997-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives as glutamate receptor antagonists |
WO1999001423A1 (en) * | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
-
2000
- 2000-01-14 JP JP2000593594A patent/JP2002534512A/en active Pending
- 2000-01-14 AU AU30335/00A patent/AU3033500A/en not_active Abandoned
- 2000-01-14 WO PCT/DK2000/000014 patent/WO2000042026A1/en not_active Application Discontinuation
- 2000-01-14 EP EP00900499A patent/EP1147094A1/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB966818A (en) * | 1960-01-14 | 1964-08-19 | Bayer Ag | 2-halo-3-mercapto-quinoxaline substitution products and process for their production |
EP0018493A1 (en) * | 1979-04-05 | 1980-11-12 | Bayer Ag | 2-Sulfonyl-quinoxalines, processes for their preparation and their use as microbicides |
EP0216299A1 (en) * | 1985-09-21 | 1987-04-01 | BASF Aktiengesellschaft | Quinoxaline derivatives, method for their preparartion and their use to protect cultivated plants against phytotoxical reaction of herbicides |
EP0338346A2 (en) * | 1988-04-11 | 1989-10-25 | Nisshin Flour Milling Co., Ltd. | Quinoxaline derivatives and antiulcer agents |
WO1995024403A1 (en) * | 1994-03-10 | 1995-09-14 | Zeneca Limited | (4,4-difluorobut-3-enylthio)-substituted heterocyclic or carbocyclic ring compounds having pesticidal activity |
WO1996030370A2 (en) * | 1995-03-27 | 1996-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole and thiadiazole derivatives, their preparation and pharmaceutical compositions useful in the treatment of thrombocytopenia |
WO1997032858A1 (en) * | 1996-03-05 | 1997-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives as glutamate receptor antagonists |
WO1999001423A1 (en) * | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
Non-Patent Citations (16)
Title |
---|
BIOORG. MED. CHEM. LETT., vol. 2, no. 9, 1992, pages 915 - 918 * |
BULL. CHEM. SOC. JPN., vol. 71, no. 5, 1998, pages 1125 - 1135 * |
CHEM. PHARM. BULL., vol. 37, no. 3, 1989, pages 618 - 620 * |
DATABASE CAPLUS [online] COLLINS, JUDITH L. ET. AL.: "CP-99,711: A nonpeptide glucagon receptor antagonist", XP002945399, retrieved from 119:131283 accession no. STN. INT. file CAPLUS Database accession no. 1993:531283 * |
DATABASE CAPLUS [online] GUILLON, J. ET. AL: "Synthesis of new ethyl 4-(3-dimethylamino) Propylmethylamino) pyrrolo(1,2-a) quinoxaline-2-carboxylate derivatives and preliminary CNS pharmacological evaluation in mice.", XP002945396, retrieved from 129:230697 accession no. STN Database accession no. 1998:515240 * |
DATABASE CAPLUS [online] IIJIMA, CHIHOKO ET. AL.: "Quinoxalines. XXVI. Reactions of 2-quinoxalinyl thiocyanate with nucleophiles.", XP002946702, retrieved from 111:232734 accession no. STN. INT. file CAPLUS Database accession no. 1989:632734 * |
DATABASE CAPLUS [online] MAHAJANSHETTI, C. S. ET. AL.: "2-Methyl-3-phenylquinoxalines and their styryl derivaties.", XP002946703, retrieved from 81:91475 accession no. STN. INT. file CAPLUS Database accession no. 1974:491475 * |
DATABASE CAPLUS [online] MOUSTAFA, O. S.: "Synthesis and reactions of new triazino thiadiazino and pyrimido thieno (2,3-b) quinoxaline.", XP002945395, retrieved from 130:3826 accession no. STN. INT. file CAPLUS Database accession no. 1998:659106 * |
DATABASE CAPLUS [online] PIRAS, SANDRA ET. AL.: "Synthesis and evaluation of gastroprotective activity of emoprazole-related benzimidazole, imidazo (4,5-b) pyridine and quinoxaline 2-substitued derivatives", XP002945398, retrieved from 120:207907 accession no. STN. INT. file CAPLUS Database accession no. 1994:207907 * |
DATABASE CAPLUS [online] SHINDE, B. R. ET. AL.: "Synthesis of quinoxaline sulfides and sulfones as antitubercular compounds.", XP002946701, retrieved from 119:131283 accession no. STN. INT. file CAPLUS Database accession no. 1990:198311 * |
DATABASE CAPLUS [online] TOMODA, HARUHIKO ET. AL.: "Synthesis and physical properties of pyrido (1' ,2': 1,2) imidazo (4,5-b) quinoxalines.", XP002945397, retrieved from 129:95461 accession no. STN. INT. file CAPLUS Database accession no. 1998:342497 * |
FARMACO, vol. 48, no. 9, 1993, pages 1249 - 1259 * |
INDIAN DRUGS, vol. 27, no. 1, 1989, pages 32 - 34 * |
INDIAN J. CHEM., vol. 12, no. 1, 1974, pages 54 - 56 * |
PHARM. PHARMACOL. COMMUN., vol. 4, no. 7, 1998, pages 319 - 324 * |
PHOSPHORUS, SULFUR SILICON RELAT. ELEM., vol. 131, 1997, pages 49 - 57 * |
Cited By (275)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8097452B2 (en) | 1998-11-20 | 2012-01-17 | Arena Pharmaceuticals, Inc. | Human orphan G protein-coupled receptors |
US8198049B2 (en) | 1998-11-20 | 2012-06-12 | Arena Pharmaceuticals, Inc. | Nucleic acids encoding RUP3 and methods of using same |
US7816492B2 (en) | 1998-11-20 | 2010-10-19 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors |
USRE42190E1 (en) | 1998-11-20 | 2011-03-01 | Arena Pharmaceuticals, Inc. | Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors |
US7893235B2 (en) | 1998-11-20 | 2011-02-22 | Arena Pharmaceuticals, Inc. | Nucleic acids encoding the GPCR, RUP3, and methods of use thereof |
US6770620B2 (en) | 2000-09-18 | 2004-08-03 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US7348340B2 (en) | 2000-11-06 | 2008-03-25 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
EP1372654A2 (en) * | 2001-04-06 | 2004-01-02 | SmithKline Beecham Corporation | Quinoline inhibitors of hyak1 and hyak3 kinases |
EP1372654A4 (en) * | 2001-04-06 | 2007-10-03 | Smithkline Beecham Corp | Quinoline inhibitors of hyak1 and hyak3 kinases |
US7087758B2 (en) * | 2001-04-06 | 2006-08-08 | Smithkline Beecham Corporation | Quinoline inhibitors of hyaki and hyak3 kinases |
EP1956020A2 (en) | 2001-05-05 | 2008-08-13 | Smithkline Beecham Plc | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity |
EP2226324A1 (en) | 2001-07-06 | 2010-09-08 | Merck Sharp & Dohme Corp. | Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines for use in the treatment of diabetes type ii |
US8217001B2 (en) | 2001-09-24 | 2012-07-10 | Imperial Innovations Limited | Modification of feeding behavior |
WO2003031432A1 (en) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
EP2243776A1 (en) | 2001-10-12 | 2010-10-27 | High Point Pharmaceuticals, LLC | Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor |
EP2305648A1 (en) | 2001-12-21 | 2011-04-06 | Novo Nordisk A/S | Amide derivatives useful as glucokinase activators |
WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
EP2329839A1 (en) | 2002-01-10 | 2011-06-08 | Imperial Innovations Limited | Modification of feeding behavior by GLP-1 and PYY |
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US7977337B2 (en) | 2002-03-27 | 2011-07-12 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
EP1956004A1 (en) | 2002-03-27 | 2008-08-13 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7799774B2 (en) | 2002-03-27 | 2010-09-21 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US8236947B2 (en) | 2002-03-27 | 2012-08-07 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7601837B2 (en) | 2002-03-27 | 2009-10-13 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
WO2003084563A1 (en) * | 2002-04-04 | 2003-10-16 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
US7919528B2 (en) | 2002-05-31 | 2011-04-05 | Glaxosmithkline Llc | Peptide deformylase inhibitors |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
EP2471533A1 (en) | 2002-06-27 | 2012-07-04 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
WO2004002481A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
WO2004052370A3 (en) * | 2002-12-11 | 2004-08-19 | 7Tm Pharma As | Quinoline compounds for use in mch receptor related disorders |
WO2004052371A2 (en) * | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Cyclic quinoline compounds for use in mch receptor related disorders |
WO2004052370A2 (en) * | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Quinoline compounds for use in mch receptor related disorders |
WO2004052371A3 (en) * | 2002-12-11 | 2004-08-19 | 7Tm Pharma As | Cyclic quinoline compounds for use in mch receptor related disorders |
EP2371378A1 (en) | 2003-01-10 | 2011-10-05 | Imperial Innovations Limited | Modification of feeding behaviour and weight control by oxyntomodulin |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
WO2005023291A3 (en) * | 2003-09-11 | 2005-04-28 | Novo Nordisk As | Use of glp1-agonists in the treatment of patients with type i diabetes |
WO2005023291A2 (en) * | 2003-09-11 | 2005-03-17 | Novo Nordisk A/S | Use of glp1-agonists in the treatment of patients with type i diabetes |
WO2005026125A1 (en) * | 2003-09-12 | 2005-03-24 | Glaxo Group Limited | Quinoline compounds and pharmaceutical compositions containing them |
US7439244B2 (en) | 2003-09-12 | 2008-10-21 | Glaxo Group Limited | Quinoline compounds and pharmeceutical compositions containing them |
WO2005030797A2 (en) | 2003-09-30 | 2005-04-07 | Novo Nordisk A/S | Melanocortin receptor agonists |
EP2298337B1 (en) * | 2003-12-09 | 2017-02-22 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
US9486504B2 (en) | 2003-12-09 | 2016-11-08 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
EP2298337A2 (en) | 2003-12-09 | 2011-03-23 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
US7576215B2 (en) | 2003-12-12 | 2009-08-18 | Wyeth | Quinolines and pharmaceutical compositions thereof |
EP2444397A1 (en) | 2004-01-06 | 2012-04-25 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
WO2005067932A1 (en) * | 2004-01-06 | 2005-07-28 | Janssen Pharmaceutica, N.V. | (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity |
US7501416B2 (en) | 2004-02-06 | 2009-03-10 | Bristol-Myers Squibb Company | Quinoxaline compounds and methods of using them |
EP2316446A1 (en) | 2004-06-11 | 2011-05-04 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
WO2006003096A1 (en) * | 2004-07-02 | 2006-01-12 | Novo Nordisk A/S | Condensed thiophene derivatives and their use as cyclic glp-1 agonists |
WO2006053906A1 (en) | 2004-11-22 | 2006-05-26 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
WO2006058923A1 (en) | 2004-12-03 | 2006-06-08 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
WO2006072881A1 (en) | 2005-01-10 | 2006-07-13 | Cortendo Invest Ab | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
EP2292653A1 (en) | 2005-02-02 | 2011-03-09 | Novo Nordisk A/S | Novel insulin derivatives |
EP2256130A1 (en) | 2005-02-02 | 2010-12-01 | Novo Nordisk A/S | Novel insulin derivatives |
WO2006082204A1 (en) | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
EP2233470A1 (en) | 2005-07-04 | 2010-09-29 | High Point Pharmaceuticals, LLC | Histamine H3 receptor antagonists |
EP2386554A1 (en) | 2005-07-04 | 2011-11-16 | High Point Pharmaceuticals, LLC | Compounds active at the histamine H3 receptor |
WO2007006814A1 (en) | 2005-07-14 | 2007-01-18 | Novo Nordisk A/S | Urea glucokinase activators |
EP2377856A1 (en) | 2005-07-14 | 2011-10-19 | Novo Nordisk A/S | Urea glucokinase activators |
WO2007015805A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | 1-amino linked compounds |
US9018164B2 (en) | 2005-11-07 | 2015-04-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
WO2007110364A1 (en) | 2006-03-28 | 2007-10-04 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine h3 receptor activity |
WO2007137968A1 (en) | 2006-05-29 | 2007-12-06 | High Point Pharmaceuticals, Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
EP2402324A1 (en) | 2006-05-29 | 2012-01-04 | High Point Pharmaceuticals, LLC | Benzodioxolylcyclopropylpiperazinylpyridazines |
US9198906B2 (en) | 2006-10-02 | 2015-12-01 | Cortendo Ab (Publ) | Ketoconazole enantiomer in humans |
WO2008059025A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
US7964732B2 (en) | 2006-11-17 | 2011-06-21 | Pfizer Inc. | Substituted bicyclocarboxyamide compounds |
US8101576B2 (en) | 2006-12-13 | 2012-01-24 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
US8669228B2 (en) | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
WO2008084044A1 (en) | 2007-01-11 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
US8900593B2 (en) | 2007-02-15 | 2014-12-02 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9447162B2 (en) | 2007-02-15 | 2016-09-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8642619B2 (en) | 2007-06-06 | 2014-02-04 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
US9403773B2 (en) | 2007-06-06 | 2016-08-02 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
US9045464B2 (en) | 2007-06-06 | 2015-06-02 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
US8269011B2 (en) | 2007-06-06 | 2012-09-18 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
US9981901B2 (en) | 2007-06-08 | 2018-05-29 | Fosun Orinove Pharmatech, Inc. | IRE-1α inhibitors |
US9241942B2 (en) | 2007-06-08 | 2016-01-26 | Mannkind Corporation | IRE-1α inhibitors |
US9546149B2 (en) | 2007-06-08 | 2017-01-17 | Mannkind Corporation | IRE-1α inhibitors |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US8981047B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Glucagon antagonists |
US9808455B2 (en) | 2007-12-12 | 2017-11-07 | Axovant Sciences Gmbh | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
EP2262364A2 (en) * | 2008-03-07 | 2010-12-22 | TransTech Pharma, Inc | Oxadiazoanthracene compounds for the treatment of diabetes |
US8524708B2 (en) | 2008-03-07 | 2013-09-03 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
US8703766B2 (en) | 2008-03-07 | 2014-04-22 | Transtech Pharma, Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
EP2262364A4 (en) * | 2008-03-07 | 2012-04-04 | Transtech Pharma Inc | Oxadiazoanthracene compounds for the treatment of diabetes |
US9120813B2 (en) | 2008-03-07 | 2015-09-01 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
US8933222B2 (en) | 2008-03-07 | 2015-01-13 | Transtech Pharma, Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10787437B2 (en) | 2008-04-02 | 2020-09-29 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
WO2009127321A1 (en) | 2008-04-18 | 2009-10-22 | Merck Patent Gmbh, | Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators |
US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8785640B2 (en) | 2008-10-23 | 2014-07-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8969382B2 (en) | 2008-10-23 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8604203B2 (en) | 2008-10-23 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8513282B2 (en) | 2008-10-23 | 2013-08-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8598205B2 (en) | 2008-10-23 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US8673908B2 (en) | 2008-11-10 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd. | Kynurenine production inhibitor |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
US9018229B2 (en) | 2008-12-05 | 2015-04-28 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
USRE45108E1 (en) | 2008-12-05 | 2014-09-02 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
US8592593B2 (en) | 2008-12-05 | 2013-11-26 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
US8304546B2 (en) | 2008-12-05 | 2012-11-06 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound and pharmaceutical composition |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US9422242B2 (en) | 2008-12-23 | 2016-08-23 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
US9974782B2 (en) | 2008-12-23 | 2018-05-22 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
US8697875B2 (en) | 2008-12-23 | 2014-04-15 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
US8207342B2 (en) | 2009-03-10 | 2012-06-26 | Gruenenthal Gmbh | Substituted 3-amino-2-mercaptoquinolines as KCNQ2/3 modulators |
US8247573B2 (en) | 2009-03-12 | 2012-08-21 | Gruenenthal Gmbh | Substituted N-(2-mercaptopyridin-3-yl)amides as KCNQ2/3 modulators |
US8399673B2 (en) | 2009-03-12 | 2013-03-19 | Gruenenthal Gmbh | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators |
US8178684B2 (en) | 2009-03-12 | 2012-05-15 | Gruenenthal Gmbh | Substituted nicotinamides as KCNQ2/3 modulators |
US8586755B2 (en) | 2009-03-12 | 2013-11-19 | Grünenthal GmbH | Substituted nicotinamides as KCNQ2/3 modulators |
CN102348692A (en) * | 2009-03-12 | 2012-02-08 | 格吕伦塔尔有限公司 | Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators |
WO2010102811A1 (en) * | 2009-03-12 | 2010-09-16 | Grünenthal GmbH | Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators |
US8987295B2 (en) | 2009-03-30 | 2015-03-24 | Transtech Pharma, Llc | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
US9175003B2 (en) | 2009-03-30 | 2015-11-03 | Vtv Therapeutics Llc | Substituted azoanthracene derivatives and intermediates for preparation thereof |
EP2413693A4 (en) * | 2009-03-30 | 2012-08-22 | Transtech Pharma Inc | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
JP2012522060A (en) * | 2009-03-30 | 2012-09-20 | トランス テック ファーマ,インコーポレイテッド | Substituted azoanthracene derivatives, pharmaceutical compositions thereof and methods of use thereof |
EP2413693A1 (en) * | 2009-03-30 | 2012-02-08 | TransTech Pharma, Inc | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
US8383644B2 (en) | 2009-03-30 | 2013-02-26 | Transtech Pharma, Inc. | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
WO2010114824A1 (en) | 2009-03-30 | 2010-10-07 | Transtech Pharma Inc | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9790263B2 (en) | 2009-06-16 | 2017-10-17 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011048614A2 (en) | 2009-10-22 | 2011-04-28 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
US8765728B2 (en) | 2009-11-16 | 2014-07-01 | Mellitech | [1,5]-diazocin derivatives |
WO2011058193A1 (en) | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9340523B2 (en) | 2009-12-30 | 2016-05-17 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
US9487571B2 (en) | 2010-01-27 | 2016-11-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
WO2011104379A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
WO2011117415A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
WO2011117416A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
US9168288B2 (en) | 2010-04-09 | 2015-10-27 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist |
US10519137B2 (en) | 2010-04-30 | 2019-12-31 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
EP3590934A1 (en) | 2010-04-30 | 2020-01-08 | Astex Therapeutics Limited | Pyrazolyl quinoxaline kinase inhibitors |
US9464071B2 (en) | 2010-04-30 | 2016-10-11 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
WO2011135376A1 (en) | 2010-04-30 | 2011-11-03 | Astex Therapeutics Limited | Pyrazolyl quinazoline kinase inhibitors |
US8895601B2 (en) | 2010-04-30 | 2014-11-25 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US9850228B2 (en) | 2010-04-30 | 2017-12-26 | Astex Therapeutics Ltd | Pyrazolyl quinoxaline kinase inhibitors |
US10548891B2 (en) | 2010-05-10 | 2020-02-04 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine |
US9150569B2 (en) | 2010-05-10 | 2015-10-06 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9783592B2 (en) | 2010-05-13 | 2017-10-10 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
EP3318561B1 (en) * | 2010-05-26 | 2021-12-22 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
US8470852B2 (en) | 2010-08-27 | 2013-06-25 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators |
US8653101B2 (en) | 2010-08-27 | 2014-02-18 | Gruenenthal Gmbh | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
US8653102B2 (en) | 2010-08-27 | 2014-02-18 | Gruenenthal Gmbh | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators |
US9073862B2 (en) | 2010-08-27 | 2015-07-07 | Gruenenthal Gmbh | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
US8618129B2 (en) | 2010-09-01 | 2013-12-31 | Gruenenthal Gmbh | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators |
US9856236B2 (en) | 2010-11-29 | 2018-01-02 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US9290478B2 (en) | 2010-11-29 | 2016-03-22 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US9249206B2 (en) | 2010-12-22 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
WO2012130866A1 (en) | 2011-03-28 | 2012-10-04 | Novo Nordisk A/S | Novel glucagon analogues |
WO2012177443A3 (en) * | 2011-06-22 | 2013-04-25 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US10174093B2 (en) | 2011-06-22 | 2019-01-08 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9758562B2 (en) | 2011-06-22 | 2017-09-12 | Indiana University and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
EA031230B1 (en) * | 2011-06-22 | 2018-12-28 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Glucagon/glp-1 receptor agonists |
US10730923B2 (en) | 2011-06-22 | 2020-08-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9486505B2 (en) | 2011-09-23 | 2016-11-08 | Novo Nordisk A/S | Glucagon analogues |
US8541368B2 (en) | 2011-09-23 | 2013-09-24 | Novo Nordisk A/S | Glucagon analogues |
CN104024257A (en) * | 2011-10-04 | 2014-09-03 | 吉利德卡利斯托加有限责任公司 | Novel quinoxaline inhibitors of PI3K |
WO2013061077A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | New compounds |
WO2013061080A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | Anticancer pyridopyrazines via the inhibition of fgfr kinases |
US10052320B2 (en) | 2011-10-28 | 2018-08-21 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US9303029B2 (en) | 2011-10-28 | 2016-04-05 | Astex Therapeutics Ltd | Substituted quinoxalines as FGFR kinase inhibitors |
US9527844B2 (en) | 2011-10-28 | 2016-12-27 | Astex Therapeutics Limited | Naphthyridine derivative compounds |
WO2013061074A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | Quinolines as fgfr kinase modulators |
US9309241B2 (en) | 2011-10-28 | 2016-04-12 | Astex Therapeutics Ltd | Naphthyridine derivative compounds |
US9309242B2 (en) | 2011-10-28 | 2016-04-12 | Astex Therapeutics Ltd | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors |
US9439896B2 (en) | 2011-10-28 | 2016-09-13 | Astex Therapeutics Ltd | Quinolines as FGFR kinase modulators |
US10039759B2 (en) | 2011-10-28 | 2018-08-07 | Astex Therapeutics Ltd | Quinolines as FGFR kinase modulators |
WO2013061081A1 (en) | 2011-10-28 | 2013-05-02 | Astex Therapeutics Limited | Anticancer benzopyrazines via the inhibition of fgfr kinases |
US10045982B2 (en) | 2011-10-28 | 2018-08-14 | Astex Therapeutics Ltd | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors |
US9757364B2 (en) | 2011-10-28 | 2017-09-12 | Astex Therapeutics Ltd | Naphthyridine derivative compounds |
WO2013069765A1 (en) | 2011-11-09 | 2013-05-16 | 協和発酵キリン株式会社 | Nitrogenated heterocyclic compound |
US9067923B2 (en) | 2011-11-09 | 2015-06-30 | Kyowa Hakko Kirin Co., Ltd. | Substituted quinoxalines |
EP3312173A1 (en) | 2011-11-09 | 2018-04-25 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
WO2013155600A1 (en) | 2012-04-16 | 2013-10-24 | Kaneq Pharma | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
US9296701B2 (en) | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9376448B2 (en) | 2012-04-24 | 2016-06-28 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9925188B2 (en) | 2012-04-24 | 2018-03-27 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors and uses thereof |
US10501439B2 (en) | 2012-04-24 | 2019-12-10 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US11008305B2 (en) | 2012-04-24 | 2021-05-18 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9592232B2 (en) | 2012-04-24 | 2017-03-14 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US11021465B2 (en) | 2012-04-24 | 2021-06-01 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10391095B2 (en) | 2012-04-24 | 2019-08-27 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9878993B2 (en) | 2012-04-24 | 2018-01-30 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors for treatment of cancer |
US10076521B2 (en) | 2012-04-24 | 2018-09-18 | Vertex Pharamceuticals Incorporated | DNA-PK inhibitors |
US10442791B2 (en) | 2012-04-24 | 2019-10-15 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10272087B2 (en) | 2012-05-30 | 2019-04-30 | Astex Therapeutics Ltd | Pteridines as FGFR inhibitors |
US9303030B2 (en) | 2012-05-30 | 2016-04-05 | Astex Therapeutics Limited | Compounds |
US9447098B2 (en) | 2012-05-30 | 2016-09-20 | Astex Therapeutics Ltd | Pteridines as FGFR inhibitors |
US9737544B2 (en) | 2012-05-30 | 2017-08-22 | Astex Therapeutics Limited | Compounds |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
WO2014045266A1 (en) | 2012-09-24 | 2014-03-27 | Ulf Eriksson | Treatment of type 2 diabetes and related conditions |
US9867869B2 (en) | 2012-12-12 | 2018-01-16 | Massachusetts Institute Of Technology | Insulin derivatives for diabetes treatment |
WO2014121885A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4 |
US10966987B2 (en) | 2013-02-15 | 2021-04-06 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9877970B2 (en) | 2013-02-15 | 2018-01-30 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9827248B2 (en) | 2013-02-15 | 2017-11-28 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US10398703B2 (en) | 2013-02-15 | 2019-09-03 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
US11369611B2 (en) | 2013-02-20 | 2022-06-28 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US10758539B2 (en) | 2013-02-20 | 2020-09-01 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9833453B2 (en) | 2013-02-20 | 2017-12-05 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US10285991B2 (en) | 2013-02-20 | 2019-05-14 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9861634B2 (en) | 2013-02-20 | 2018-01-09 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9340557B2 (en) | 2013-03-12 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US11813267B2 (en) | 2013-03-12 | 2023-11-14 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10258627B2 (en) | 2013-03-12 | 2019-04-16 | Vertex Pharmaceutical Incorporated | DNA-PK inhibitors |
US10786512B2 (en) | 2013-03-12 | 2020-09-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9359380B2 (en) | 2013-03-12 | 2016-06-07 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9987284B2 (en) | 2013-03-12 | 2018-06-05 | Vertex Pharmaceuticals Incorporated | Substituted benzooxadiazole DNA-PK inhibitors |
US10973830B2 (en) | 2013-03-12 | 2021-04-13 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US9474790B2 (en) | 2013-04-18 | 2016-10-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
US9751927B2 (en) | 2013-04-18 | 2017-09-05 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
US9493426B2 (en) | 2013-04-26 | 2016-11-15 | Astex Therapeutics Limited | Quinazolinone derivatives useful as FGFR kinase modulators |
US10039761B2 (en) | 2013-10-17 | 2018-08-07 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US10716789B2 (en) | 2013-10-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US10975090B2 (en) | 2013-11-01 | 2021-04-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9790232B2 (en) | 2013-11-01 | 2017-10-17 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US11713323B2 (en) | 2013-11-01 | 2023-08-01 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10160765B2 (en) | 2013-11-01 | 2018-12-25 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10618906B2 (en) | 2013-11-01 | 2020-04-14 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9902714B2 (en) | 2014-03-26 | 2018-02-27 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as FGFR kinase modulators |
US10421747B2 (en) | 2014-03-26 | 2019-09-24 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as FGFR kinase modulators |
US10716787B2 (en) | 2014-03-26 | 2020-07-21 | Astex Therapeutics Ltd | Combinations |
WO2015144803A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
US10085982B2 (en) | 2014-03-26 | 2018-10-02 | Astex Therapeutics Ltd | Combinations |
US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
US11918576B2 (en) | 2014-03-26 | 2024-03-05 | Astex Therapeutics Ltd | Combination of an FGFR inhibitor and a CMET inhibitor |
WO2015160678A1 (en) | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Sitagliptin tannate complex |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
WO2016034708A1 (en) | 2014-09-04 | 2016-03-10 | Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet | Use of a quinoxaline derivative in an imaging method |
DE102014112747A1 (en) | 2014-09-04 | 2016-03-10 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Use of a quinoxaline derivative in an imaging process |
US11684620B2 (en) | 2015-02-10 | 2023-06-27 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10898482B2 (en) | 2015-02-10 | 2021-01-26 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US11304932B2 (en) | 2015-07-15 | 2022-04-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US11155555B2 (en) | 2015-09-23 | 2021-10-26 | Janssen Pharmaceutica Nv | Compounds |
WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
US11542247B2 (en) | 2015-09-23 | 2023-01-03 | Janssen Pharmaceutica Nv | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer |
US11021487B2 (en) | 2016-09-08 | 2021-06-01 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US11104685B2 (en) | 2016-09-08 | 2021-08-31 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10626121B2 (en) | 2016-09-08 | 2020-04-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10766907B2 (en) | 2016-09-08 | 2020-09-08 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
US11980633B2 (en) | 2016-09-27 | 2024-05-14 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
WO2018167194A1 (en) | 2017-03-15 | 2018-09-20 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
WO2019217165A1 (en) * | 2018-05-08 | 2019-11-14 | Vtv Therapeutics Llc | Therapeutic uses of glp1r agonists |
WO2019219714A1 (en) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
WO2020074958A1 (en) | 2018-10-12 | 2020-04-16 | Strongbridge Dublin Limited | Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism |
Also Published As
Publication number | Publication date |
---|---|
JP2002534512A (en) | 2002-10-15 |
WO2000042026B1 (en) | 2000-10-05 |
EP1147094A1 (en) | 2001-10-24 |
AU3033500A (en) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1147094A1 (en) | Non-peptide glp-1 agonists | |
TWI383981B (en) | Benzofuranyl derivatives | |
JP4800964B2 (en) | Heteroarylindolecarboxamides and analogs thereof for use as glucokinase activators in the treatment of obesity | |
JP5501369B2 (en) | Soluble guanylate cyclase activator | |
KR100856164B1 (en) | INDOZOLONE DERIVATIVES AS 11beta;-HSD1 INHIBITORS | |
EP2415767B1 (en) | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | |
JP2012509877A5 (en) | ||
TW200413379A (en) | Fused azole-pyrimidine derivatives | |
WO2006051704A1 (en) | Imine compound | |
JP2009506127A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
US6927214B1 (en) | Non-peptide GLP-1 agonists | |
JP2010527999A (en) | Prinones and 1H-imidazopyridinones as PKC-θ inhibitors | |
TW200815393A (en) | Derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors | |
EP1973916A1 (en) | PYRROLO Ýl,2-A¨QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | |
TW200826927A (en) | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | |
WO2003057161A2 (en) | BENZOTHIENO [3,2-c]PYRAZOLYL AND BENZOFURANO [3,2-c] PYRAZOLYL COMPOUNDS, THEIR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR AND INTERMEDIATE COMPOUNDS THEREOF | |
JP2013510137A (en) | Imidazopyridine derivatives | |
JP5331953B2 (en) | 3-Amino-pyridine derivatives for the treatment of metabolic disorders | |
JP3204456B2 (en) | 2,7-substituted octahydro-pyrrolo [1,2-A] pyrazine derivatives | |
JP2012515760A (en) | Substituted pyrazinonamide | |
JP5647379B2 (en) | Quinolinyl glucagon receptor modulator | |
US6232310B1 (en) | Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use | |
EP2801573A1 (en) | Hydantoine derivatives as CD38 inhibitors | |
SK14672003A3 (en) | Imidazotriazones derivatives and their use against inflammatory processes and/or immune diseases | |
WO1999031098A1 (en) | Novel pyridine and pyrimidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
B | Later publication of amended claims | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000900499 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 593594 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000900499 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000900499 Country of ref document: EP |